Analyst Price Target is $44.93
▼ -4.35% Downside Potential
This price target is based on 13 analysts offering 12 month price targets for PPD in the last 3 months. The average price target is $44.93, with a high forecast of $48.00 and a low forecast of $40.00. The average price target represents a -4.35% upside from the last price of $46.97.
Current Consensus is
The current consensus among 13 polled investment analysts is to hold stock in PPD. This rating has held steady since May 2020, when it changed from a Buy consensus rating.
PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.